BACKGROUND: Epidemiologic studies have shown a relationship between glycated hemoglobin levels and cardiovascular events in patients with type 2 diabetes. We investigated whether intensive therapy to target normal glycated hemoglobin levels would reduce cardiovascular events in patients with type 2 diabetes who had either established cardiovascular disease or additional cardiovascular risk factors. METHODS: In this randomized study, 10,251 patients (mean age, 62.2 years) with a median glycated hemoglobin level of 8.1% were assigned to receiveintensive therapy (targeting a glycated hemoglobin level below 6.0%) or standard therapy (targeting a level from 7.0 to 7.9%). Of these patients, 38% were women, and 35% had had a previous cardiovascular event. The primary outcome was a composite of nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes. The finding of higher mortality in the intensive-therapy group led to a discontinuation of intensive therapy after a mean of 3.5 years of follow-up. RESULTS: At 1 year, stable median glycated hemoglobin levels of 6.4% and 7.5% were achieved in the intensive-therapy group and the standard-therapy group, respectively. During follow-up, the primary outcome occurred in 352 patients in the intensive-therapy group, as compared with 371 in the standard-therapy group (hazard ratio, 0.90; 95% confidence interval [CI], 0.78 to 1.04; P=0.16). At the same time, 257 patients in the intensive-therapy group died, as compared with 203 patients in the standard-therapy group (hazard ratio, 1.22; 95% CI, 1.01 to 1.46; P=0.04). Hypoglycemia requiring assistance and weight gain of more than 10 kg were more frequent in the intensive-therapy group (P<0.001). CONCLUSIONS: As compared with standard therapy, the use of intensive therapy to target normal glycated hemoglobin levels for 3.5 years increased mortality and did not significantly reduce major cardiovascular events. These findings identify a previously unrecognized harm of intensive glucose lowering in high-risk patients with type 2 diabetes. (ClinicalTrials.gov number, NCT00000620.) 2008 Massachusetts Medical Society
RCT Entities:
BACKGROUND: Epidemiologic studies have shown a relationship between glycated hemoglobin levels and cardiovascular events in patients with type 2 diabetes. We investigated whether intensive therapy to target normal glycated hemoglobin levels would reduce cardiovascular events in patients with type 2 diabetes who had either established cardiovascular disease or additional cardiovascular risk factors. METHODS: In this randomized study, 10,251 patients (mean age, 62.2 years) with a median glycated hemoglobin level of 8.1% were assigned to receive intensive therapy (targeting a glycated hemoglobin level below 6.0%) or standard therapy (targeting a level from 7.0 to 7.9%). Of these patients, 38% were women, and 35% had had a previous cardiovascular event. The primary outcome was a composite of nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes. The finding of higher mortality in the intensive-therapy group led to a discontinuation of intensive therapy after a mean of 3.5 years of follow-up. RESULTS: At 1 year, stable median glycated hemoglobin levels of 6.4% and 7.5% were achieved in the intensive-therapy group and the standard-therapy group, respectively. During follow-up, the primary outcome occurred in 352 patients in the intensive-therapy group, as compared with 371 in the standard-therapy group (hazard ratio, 0.90; 95% confidence interval [CI], 0.78 to 1.04; P=0.16). At the same time, 257 patients in the intensive-therapy group died, as compared with 203 patients in the standard-therapy group (hazard ratio, 1.22; 95% CI, 1.01 to 1.46; P=0.04). Hypoglycemia requiring assistance and weight gain of more than 10 kg were more frequent in the intensive-therapy group (P<0.001). CONCLUSIONS: As compared with standard therapy, the use of intensive therapy to target normal glycated hemoglobin levels for 3.5 years increased mortality and did not significantly reduce major cardiovascular events. These findings identify a previously unrecognized harm of intensive glucose lowering in high-risk patients with type 2 diabetes. (ClinicalTrials.gov number, NCT00000620.) 2008 Massachusetts Medical Society
Authors: Randal J Thomas; Pasquale J Palumbo; L Joseph Melton; Véronique L Roger; Jeanine Ransom; Peter C O'Brien; Cynthia L Leibson Journal: Arch Intern Med Date: 2003-02-24
Authors: C Abraira; J Colwell; F Nuttall; C T Sawin; W Henderson; J P Comstock; N V Emanuele; S R Levin; I Pacold; H S Lee Journal: Arch Intern Med Date: 1997-01-27
Authors: Elizabeth Selvin; Spyridon Marinopoulos; Gail Berkenblit; Tejal Rami; Frederick L Brancati; Neil R Powe; Sherita Hill Golden Journal: Ann Intern Med Date: 2004-09-21 Impact factor: 25.391
Authors: Connie Kingry; Arnaud Bastien; Gillian Booth; Therese S Geraci; Brenda R Kirpach; Laura C Lovato; Karen L Margolis; Yves Rosenberg; JoAnne M Sperl-Hillen; Laura Vargo; Jeff D Williamson; Jeffrey L Probstfield Journal: Am J Cardiol Date: 2007-04-12 Impact factor: 2.778
Authors: Denise E Bonds; Ella Mae Kurashige; Richard Bergenstal; David Brillon; Michael Domanski; James V Felicetta; Vivian A Fonseca; Kathleen Hall; Irene Hramiak; Michael E Miller; Kwame Osei; Denise G Simons-Morton Journal: Am J Cardiol Date: 2007-04-17 Impact factor: 2.778
Authors: Zvonko Milicevic; Itamar Raz; Krzysztof Strojek; Jan Skrha; Meng H Tan; John W Wyatt; Scott D Beattie; David C Robbins Journal: J Diabetes Complications Date: 2005 Mar-Apr Impact factor: 2.852
Authors: M L Norgaard; S S Andersen; T K Schramm; F Folke; C H Jørgensen; M L Hansen; C Andersson; D M Bretler; A Vaag; L Køber; C Torp-Pedersen; G H Gislason Journal: Diabetologia Date: 2010-05-09 Impact factor: 10.122
Authors: Ivana Semova; Amy E Levenson; Joanna Krawczyk; Kevin Bullock; Kathryn A Williams; R Paul Wadwa; Philip R Khoury; Thomas R Kimball; Elaine M Urbina; Sarah D de Ferranti; David M Maahs; Lawrence M Dolan; Amy S Shah; Clary B Clish; Sudha B Biddinger Journal: Pediatr Diabetes Date: 2020-09-15 Impact factor: 4.866
Authors: Elbert S Huang; Neda Laiteerapong; Jennifer Y Liu; Priya M John; Howard H Moffet; Andrew J Karter Journal: JAMA Intern Med Date: 2014-02-01 Impact factor: 21.873